A composition comprising (a) an oligomeric compound comprising one or more tricyclo-deoxyribonucleic acid (tc-DNA) nucleosides comprising a compound of Formula, wherein said oligomeric compound comprises from 5 to 40 monomer subunits; and (b) one or more lipid moieties, wherein each one or more lipid moiety is independently of each other selected from a fatty acid moiety, a fatty diacid moiety, a glycerolipid moiety, a glycerophospholipid moiety, a sphingolipid moiety, a phospholipid, an alkylphosphate moiety, and an alkylphosphonate moiety; wherein said one or more lipid moiety is covalently linked to said oligomeric compound at the 5' terminus or at the 3' terminus of said oligomeric compound either directly or via a spacer; wherein in Formula: Bx is a nucleobase; one of T 1 and T 2 is an internucleosidic linkage group, and the other of T 1 and T 2 is OR 1, OR 2, a 5' terminal group, a 3' terminal group or a internucleosidic linkage group, wherein R 1 is H or a hydroxyl protecting group, and R 2 is a phosphorus moiety; q 1, q 2, q 3, q 4 and q 5 are each independently selected from the group consisting of hydrogen, halogen, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, substituted C 1-6 alkyl, substituted C 2-6 alkenyl, substituted C 2-6 alkynyl, and -(CH 2).-C -R 6 ', wherein n is 0 to 6 and wherein R 6 ' is selected from the group consisting of OH, NH 2, O-C 1-32 alkyl and NH-C 1-32 alkyl; z 1 and z 2 are each independently selected from the group consisting of H, halogen, C 1-6 alkyl, C 1-6 alkoxyl, O-C 2-6 alkenyl, O-C 2-6 alkynyl, substituted C 1-6 alkyl, substituted C 1-6 alkoxy, substituted O-C 2-6 alkenyl, and substituted O-C 2-6 alkynyl; or a pharmaceutically-acceptable salt thereof. (a) an oligomeric compound comprising one or more tricyclo-deoxyribonucleic acid (tc-DNA) nucleosides comprising a compound of Formula, wherein said oligomeric compound comprises from 5 to 40 monomer subunits; and (b) one or more lipid moieties, wherein each one or more lipid moiety is independently of each other selected from a fatty acid moiety, a fatty diacid moiety, a glycerolipid moiety, a glycerophospholipid moiety, a sphingolipid moiety, a phospholipid, an alkylphosphate moiety, and an alkylphosphonate moiety; wherein said one or more lipid moiety is covalently linked to said oligomeric compound at the 5' terminus or at the 3' terminus of said oligomeric compound either directly or via a spacer; wherein in Formula: Bx is a nucleobase; one of T 1 and T 2 is an internucleosidic linkage group, and the other of T 1 and T 2 is OR 1, OR 2, a 5' terminal group, a 3' terminal group or a internucleosidic linkage group, wherein R 1 is H or a hydroxyl protecting group, and R 2 is a phosphorus moiety; q 1, q 2, q 3, q 4 and q 5 are each independently selected from the group consisting of hydrogen, halogen, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, substituted C 1-6 alkyl, substituted C 2-6 alkenyl, substituted C 2-6 alkynyl, and -(CH 2).-C -R 6 ', wherein n is 0 to 6 and wherein R 6 ' is selected from the group consisting of OH, NH 2, O-C 1-32 alkyl and NH-C 1-32 alkyl; z 1 and z 2 are each independently selected from the group consisting of H, halogen, C 1-6 alkyl, C 1-6 alkoxyl, O-C 2-6 alkenyl, O-C 2-6 alkynyl, substituted C 1-6 alkyl, substituted C 1-6 alkoxy, substituted O-C 2-6 alkenyl, and substituted O-C 2-6 alkynyl; or a pharmaceutically-acceptable salt thereof. Bx is a nucleobase; one of T 1 and T 2 is an internucleosidic linkage group, and the other of T 1 and T 2 is OR 1, OR 2, a 5' terminal group, a 3' terminal group or a internucleosidic linkage group, wherein R 1 is H or a hydroxyl protecting group, and R 2 is a phosphorus moiety; q 1, q 2, q 3, q 4 and q 5 are each independently selected from the group consisting of hydrogen, halogen, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, substituted C 1-6 alkyl, substituted C 2-6 alkenyl, substituted C 2-6 alkynyl, and -(CH 2).-C -R 6 ', wherein n is 0 to 6 and wherein R 6 ' is selected from the group consisting of OH, NH 2, O-C 1-32 alkyl and NH-C 1-32 alkyl; z 1 and z 2 are each independently selected from the group consisting of H, halogen, C 1-6 alkyl, C 1-6 alkoxyl, O-C 2-6 alkenyl, O-C 2-6 alkynyl, substituted C 1-6 alkyl, substituted C 1-6 alkoxy, substituted O-C 2-6 alkenyl, and substituted O-C 2-6 alkynyl; or a pharmaceutically-acceptable salt thereof.